Related Symbol
avatar
@ProduceCut309 3 weeks ago

Lilly’s 2026 Outlook Just Got Juicier

Lilly’s 2026 Outlook Just Got Juicier

Anyone else watching right now? They just guided 2026 profit higher, and honestly the strength makes sense. Demand for their diabetes and GLP 1 drugs is still ripping, and this isn’t just hype. Real revenue and margins are showing up. That’s why a lot of people are staying bullish on . They’re not chasing trends, they’re actually selling must have meds and stacking cash. That kind of business usually holds up way better when markets get shaky. That said, if you’re already sitting on solid gains, don’t ignore the chance of some near term pullbacks. Big guidance runs can cool off once reality sets in. For long term holders though, this still feels like a stay patient and let it compound type of stock. Curious what everyone’s doing here. Holding strong, adding on dips, or trimming a little profit?

@Julia1007 3 weeks ago

Still bullish. I’d hold core and maybe trim a little into strength. Hard to argue with that kind of demand.

@JaneWilliams 3 weeks ago

Fair take, but I’m staying cautious after this run.